A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Denali Therapeutics announced that results from its open-label Phase 1/2 trial of tividenofusp alfa for Hunter syndrome were published in the January 1, 2026 issue of The New England Journal of ...

DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.

Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...

In her first new beauty round-up of the year, Sally Foran picks some of January's top skincare, makeup and hair releases ...

Scientists have long assumed that once the smooth cartilage in a damaged knee wears away, the body has little chance of ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Formerly Somite AI, the rebranded company aims to broaden the regenerative medicine landscape by building AI models that ...

An artificial saliva in the form of a mouthwash, produced with the CANECPI-5 protein extracted from sugarcane and modified in ...

This perspective argues that Parkinson’s disease may involve functional iron deficiency, where bioavailable iron is limited despite normal or elevated total iron in the brain. The authors propose that ...

Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.